Tech Company Financing Transactions
Adynxx Funding Round
On 1/11/2017, Adynxx raised $16 million in Series B funding from TPG Biotech and Domain Associates.
Transaction Overview
Company Name
Announced On
1/11/2017
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Series B
Investors
TPG Biotech (Lead Investor) (Heath Lukatch)
Domain Associates (Dennis Podlesak)
Proceeds Purpose
Proceeds from the financing will be used to fund the continued development of the company's lead program, AYX1 for the reduction of acute pain and prevention of chronic pain following surgery.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
100 Pine St. 500
San Francisco, CA 94111
USA
San Francisco, CA 94111
USA
Phone
Website
Email Address
Overview
The company is dedicated to developing the next breakthrough therapeutic treatments for chronic pain.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rick Orr
Chief Medical Officer
Donald Manning
Chief Scientific Officer
Julien Mamet
Controller
Dina Gonzalez
VP - Operations
William Martin
VP - Regulatory Affairs
Scott Harris
Browse more venture capital transactions:
Prev: 1/11/2017: TiqIQ venture capital transaction
Next: 1/11/2017: Enfusion Systems venture capital transaction
Share this article
News on VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs